We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NSA
851
DELISTED
National Storage Affiliates Trust
NSA
| $718K | ﹤0.01% |
25,455
+1,682
| +7% | +$50.1K |
|
852
Assurant
AIZ
$13.9B
| $701K | ﹤0.01% |
2,912
-4,632
| -61% | -$1.03M |
|
853
iShares Russell 2000 ETF
IWM
$79.1B
| $692K | ﹤0.01% |
+2,811
| New | +$691K |
|
854
StoneCo
STNE
$2.67B
| $684K | ﹤0.01% |
46,242
+14,425
| +45% | +$241K |
|
855
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
$66.2B
| $681K | ﹤0.01% |
8,132
+845
| +12% | +$71K |
|
|
OKLO
856
Oklo
OKLO
$6.41B
| $679K | ﹤0.01% |
+9,457
| New | +$1.05M |
|
857
Globe Life
GL
$14B
| $667K | ﹤0.01% |
4,767
| – | – |
|
858
Itron
ITRI
$4.48B
| $666K | ﹤0.01% |
7,172
| – | – |
|
859
Quanterix
QTRX
$159M
| $662K | ﹤0.01% |
104,039
-460,542
| -82% | -$2.86M |
|
860
Diamondrock Hospitality Co
DRH
$2.69B
| $661K | ﹤0.01% |
73,808
+3,418
| +5% | +$29.1K |
|
861
EPAM Systems
EPAM
$5.58B
| $660K | ﹤0.01% |
3,220
| – | – |
|
|
NZUS
862
DELISTED
State Street SPDR MSCI USA Climate Paris Aligned ETF
NZUS
| $659K | ﹤0.01% |
18,327
+5,780
| +46% | +$206K |
|
863
Compañía de Minas Buenaventura
BVN
$7.68B
| $655K | ﹤0.01% |
23,525
+31
| +0.1% | +$774 |
|
864
Legend Biotech
LEGN
$3.65B
| $647K | ﹤0.01% |
29,782
+11,456
| +63% | +$328K |
|
865
Douglas Emmett
DEI
$2.05B
| $638K | ﹤0.01% |
58,079
+519
| +0.9% | +$6.5K |
|
866
Li Auto
LI
$14.4B
| $637K | ﹤0.01% |
37,624
+8,782
| +30% | +$174K |
|
867
WIX.com
WIX
$2.56B
| $634K | ﹤0.01% |
6,106
| – | – |
|
868
National Grid
NGG
$79.3B
| $634K | ﹤0.01% |
8,200
-118
| -1% | -$8.88K |
|
869
State Street SPDR Dow Jones Industrial Average ETF Trust
DIA
$45B
| $632K | ﹤0.01% |
+1,316
| New | +$623K |
|
|
DAY
870
DELISTED
Dayforce
DAY
| $624K | ﹤0.01% |
9,028
| – | – |
|
871
Wynn Resorts
WYNN
$10.3B
| $612K | ﹤0.01% |
5,085
| – | – |
|
872
Revvity
RVTY
$12.6B
| $601K | ﹤0.01% |
6,213
-4,691
| -43% | -$450K |
|
873
Sunstone Hotel Investors
SHO
$2.19B
| $583K | ﹤0.01% |
65,218
-49
| -0.1% | -$449 |
|
874
Pinnacle West Capital
PNW
$12.4B
| $573K | ﹤0.01% |
6,455
| – | – |
|
875
Moderna
MRNA
$21.6B
| $567K | ﹤0.01% |
19,225
| – | – |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.